#1 Clinical Trials Search in Europe

Cloxacillin

Cloxacillin is an antibiotic medication that has been studied in several clinical trials for treating various types of staphylococcal infections. These trials have examined the efficacy and safety of cloxacillin compared to other antibiotics, as well as different administration methods, for conditions like bacteremia, bone and joint infections, and catheter-related infections caused by Staphylococcus aureus bacteria.

Table of Contents

What is Cloxacillin?

Cloxacillin is an antibiotic medication that belongs to the class of drugs called penicillins. It is specifically designed to treat infections caused by certain types of bacteria, particularly those that are resistant to other penicillin antibiotics. Cloxacillin is also known by other names such as Cloxacillin Sodium[1].

Uses of Cloxacillin

Cloxacillin is primarily used to treat infections caused by a type of bacteria called Staphylococcus aureus, especially strains that are methicillin-susceptible (MSSA). This means the bacteria can still be killed by certain antibiotics like cloxacillin. Some of the conditions that cloxacillin is used to treat include:

  • Bacteremia: This is a serious condition where bacteria are present in the bloodstream. Cloxacillin is often used to treat bacteremia caused by Staphylococcus aureus[2].
  • Bone and joint infections: Cloxacillin can be effective in treating infections that affect the bones and joints[3].
  • Skin and soft tissue infections: These are infections that affect the skin and the tissues underneath it.
  • Catheter-related infections: Cloxacillin may be used to prevent or treat infections associated with medical devices like catheters[4].

How Cloxacillin is Administered

Cloxacillin is typically administered intravenously (through a vein) in hospital settings. The dosage and frequency can vary depending on the severity of the infection and other patient factors. Some common administration methods include:

  • Intermittent infusions: Cloxacillin may be given every 4 or 6 hours, with doses ranging from 2 grams to 12 grams per day[2][1].
  • Continuous infusion: In some cases, cloxacillin may be administered continuously over 24 hours[3].

The duration of treatment can vary but is often around 14 days for serious infections like bacteremia[5].

Effectiveness of Cloxacillin

Cloxacillin has been shown to be effective in treating various bacterial infections, particularly those caused by Staphylococcus aureus. Its effectiveness is often measured by factors such as:

  • Resolution of fever and other symptoms of infection
  • Clearance of bacteria from the bloodstream
  • Prevention of infection-related complications
  • Overall survival rates of patients

Research is ongoing to compare the effectiveness of cloxacillin to other antibiotics and to determine the best ways to administer it[2][3].

Comparison with Other Antibiotics

Cloxacillin is often compared to other antibiotics used to treat similar infections. Some of these comparisons include:

  • Cefazolin: Studies are being conducted to compare the effectiveness of cloxacillin to cefazolin in treating Staphylococcus aureus infections[2].
  • Vancomycin: For methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin is often used instead of cloxacillin[1].
  • Oral antibiotics: Research is exploring whether switching from intravenous cloxacillin to oral antibiotics like trimethoprim-sulfamethoxazole or clindamycin can be effective for certain patients[5][1].

Potential Side Effects

Like all medications, cloxacillin can cause side effects. Some potential side effects include:

  • Allergic reactions: As a penicillin antibiotic, cloxacillin can cause allergic reactions in some people.
  • Kidney problems: High doses of cloxacillin may affect kidney function in some patients.
  • Gastrointestinal issues: Nausea, vomiting, or diarrhea can occur.
  • Liver function changes: In rare cases, cloxacillin may affect liver enzymes.
  • Complications related to intravenous therapy: These can include issues like thrombophlebitis (inflammation of a vein)[5].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of cloxacillin:

  • Comparing continuous versus intermittent infusions of cloxacillin for bone and joint infections[3].
  • Evaluating the effectiveness of cloxacillin compared to cefazolin for Staphylococcus aureus bloodstream infections[2].
  • Investigating the possibility of switching from intravenous to oral antibiotics in certain cases of Staphylococcus aureus bacteremia[5][1].

These studies aim to optimize the use of cloxacillin and improve patient outcomes in various infectious conditions.

Aspect Details
Primary Use Treatment of Staphylococcus aureus infections, including bacteremia, bone and joint infections, and catheter-related infections
Administration Typically intravenous, with dosages around 2 grams every 4-6 hours (may vary based on infection type and severity)
Comparisons Studied against antibiotics like cefazolin, benzylpenicillin, and vancomycin in clinical trials
Advantages Narrow spectrum of activity, potentially reducing risk of antibiotic resistance
Side Effects Can include gastrointestinal upset, rash, liver enzyme abnormalities, and allergic reactions
Special Considerations Dosing may need adjustment for patients with renal impairment; continuous vs. intermittent infusion being studied

FAQ

  • What is cloxacillin used to treat? Cloxacillin is primarily used to treat infections caused by Staphylococcus aureus bacteria, including bloodstream infections (bacteremia), bone and joint infections, and catheter-related infections.
  • How is cloxacillin typically administered? Cloxacillin is usually administered intravenously (through an IV) in hospital settings. Common dosages are 2 grams every 4-6 hours, though exact dosing depends on the specific infection being treated.
  • How does cloxacillin compare to other antibiotics? Clinical trials have compared cloxacillin to antibiotics like cefazolin, benzylpenicillin, and vancomycin. Results suggest cloxacillin is generally as effective as these other options for treating susceptible staphylococcal infections.
  • Are there any advantages to using cloxacillin? Cloxacillin has a narrow spectrum of activity, primarily targeting Staphylococcus aureus. This targeted approach may help reduce the risk of antibiotic resistance compared to broader-spectrum antibiotics.
  • What are some potential side effects of cloxacillin? Potential side effects of cloxacillin can include gastrointestinal upset, rash, liver enzyme abnormalities, and allergic reactions. Clinical trials monitor for these and other adverse events to evaluate the drug's safety profile.

Ongoing Clinical Trials on Cloxacillin

  • Study comparing dalbavancin to standard antibiotic treatment for patients with periprosthetic joint infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Comparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Treating Acute Osteomyelitis in Children with Amoxicillin and Cloxacillin Compared to Standard Hospital Care

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Benzylpenicillin and Cloxacillin for Treating Staphylococcus Aureus Blood Infection in Patients

    Recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

  • Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on How Kidney Function Estimates Help Adjust Cloxacillin Dosing in Patients with Staphylococcus aureus Bacteremia

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on Early Oral Antibiotic Treatment for Vertebral Osteomyelitis Using Cefuroxime, Dicloxacillin, and Ceftriaxone for Adult Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • A study on the use of vancomycin and a drug combination for treating infections in children through continuous antibiotic infusion.

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious infections throughout the body.
  • Methicillin-susceptible Staphylococcus aureus (MSSA): Strains of Staphylococcus aureus bacteria that can be treated with methicillin and similar antibiotics like cloxacillin.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Continuous infusion: A method of administering medication where the drug is given slowly and constantly over a period of time, rather than in separate doses.
  • Intermittent infusion: A method of administering medication where the drug is given in separate doses at scheduled intervals.
  • Minimal inhibitory concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacteria.
  • Osteomyelitis: An infection of the bone, which can be caused by Staphylococcus aureus bacteria.
  • Septic arthritis: An infection in a joint, often caused by bacteria like Staphylococcus aureus.
  • Catheter-related infection: An infection associated with the use of intravascular catheters, which can be caused by bacteria like Staphylococcus aureus.

References

  1. https://clinicaltrials.gov/study/NCT06336824
  2. https://clinicaltrials.gov/study/NCT03248063
  3. https://clinicaltrials.gov/study/NCT03246360
  4. https://clinicaltrials.gov/study/NCT00885300
  5. https://clinicaltrials.gov/study/NCT01792804